In the past year, biopharmaceutical giant Gilead has been a major player in the hepatitis C treatment space with its breakthrough hepatitis C star drug Sovaldi and hepatitis C cocktail Harvoni. The latest reports of Gilead’s new hepatitis C drug, velpatasvir + sofosbuvir combination, will be filed in the EU at the end of the year, which will be Gilead’s third marketed drug for hepatitis C treatment. The drug is a fixed-dose combination of Sovaldi and velpatasvir, an experimental NS5A inhibitor, administered once daily. The primary goal of each study is complete cure, or a sustained virologic response, at 12 weeks after completing treatment. At the 2015 American Liver Conference, Gilead presented the results of a study using this combination to treat 760 patients with hepatitis C, 5 genotypes, with a 99% maintenance response rate through 12 weeks of treatment. where velpatasvir is another NS5A inhibitor that replaces ledipasvir in Gilead II. For a long time, the only treatment option for patients with compensated dyscirrhosis was to undergo liver transplantation. clinical studies of DDS drugs approved in 2015 have shown that they can safely and effectively treat HCV infection in patients with compensated dyscirrhosis, and this successful treatment is associated with early enhancement of liver function. The only currently approved prescription for the treatment of HCV in patients with compensated dyscirrhosis is ledipasvirCsofosbuvir plus ribavirin for a 24-week course. This has been approved in the European Cup for the treatment of HCV genotypes 1 and 4. Researchers have published clinical phase III results of Gilead’s new drug velpatasvir in combination with sofosbuvir for the treatment of HCV infection in patients with compensated dysfunctional cirrhosis. Patients with HCV genotypes 1-6 included in this Phase III, unblinded clinical trial. These patients were either previously treated or untreated, but all had decompensated cirrhosis. The patients were randomized equally into three groups. The first group was treated with the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir once a week for 12 weeks; the second group was treated with sofosbuvir-velpatasvir plus ribavirin, also for 12 weeks; and the third group was treated with sofosbuvir- velpatasvir for 24 weeks of treatment. The primary endpoint was a sustained viral response at 12 weeks after the end of treatment. A total of 267 patients were enrolled in this trial. The six genotypes were 78%, 4%, 15%, 3%, 0, and less than 1%, in that order. The overall percentage of sustained viral response was 83%. There was no significant difference in the proportion of sustained viral response between the three groups. This study showed that sofosbuvirCvelpatasvir achieved a high proportion of sustained viral response with or without ribavirin for 12 weeks and sofosbuvirCvelpatasvir for 24 weeks. Advances in hepatitis C medications can be described as rapidly evolving and evangelical, and it is possible for patients with hepatitis C to make the hepatitis C virus disappear completely even if they progress to hepatitis cirrhosis loss of compensation.